Abstract
We present a novel solid-phase based (45)Ti radiolabeling methodology and the implementation of (45)Ti-PET in titanium-based antineoplastics using the showcase compound [(45)Ti](salan)Ti(dipic). This development is intended to allow elucidation of the biodistribution and pharmacokinetics of promising new Ti-based therapeutics.
| Original language | English |
|---|---|
| Journal | Journal of Medicinal Chemistry |
| Volume | 58 |
| Issue number | 18 |
| Pages (from-to) | 7591-5 |
| Number of pages | 5 |
| ISSN | 0022-2623 |
| DOIs | |
| Publication status | Published - 24 Sept 2015 |
Keywords
- Animals
- Antineoplastic Agents
- Coordination Complexes
- HT29 Cells
- Humans
- Mice, Nude
- Positron-Emission Tomography
- Radiopharmaceuticals
- Solid-Phase Synthesis Techniques
- Tissue Distribution
- Titanium
- Xenograft Model Antitumor Assays
Fingerprint
Dive into the research topics of 'Bringing Radiotracing to Titanium-Based Antineoplastics: Solid Phase Radiosynthesis, PET and ex Vivo Evaluation of Antitumor Agent [(45)Ti](salan)Ti(dipic)'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS